Two respected radiology organizations have issued a stark warning on the new recommendations, stating that they risk confusing patients and “may contribute to thousands of additional breast cancer deaths each year.”
"This case reflects a troubling pattern in which payers, dissatisfied with IDR results, increasingly try to attack those outcomes outside the framework Congress created," Rad Partners says.
“Expanding residency slots and mitigating workforce attrition will be necessary to mitigate increasing workforce gaps," experts write in the Journal of the American College of Radiology.
Johnson & Johnson is now the third company with an FDA-approved PFA system in its portfolio, joining Medtronic and Boston Scientific. Varipulse previously gained CE mark approval in February.
FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
